Search results
Results from the WOW.Com Content Network
The chief executive of the agency is Yasuhiro Fujiwara, former head of the National Cancer Center Japan. From 2008 to 2018, the chief executive of the agency was Tatsuya Kondo, a neurosurgeon and graduate of the University of Tokyo.
This article needs to be updated.The reason given is: there was a significant revision to Japan's Pharmaceuticals and Medical Devices Act (PMD Act) in December 4, 2019 (令和 元 年12月 4日) and certain articles in this revised PMD Act took effect April 1, 2020, September 1, 2020, and August 1, 2021; other articles will take effect Dec. 1, 2022 (see also: https://www.natlawreview.com ...
Sakigake (さきがけ, lit. "pathfinder", "harbinger") is a drug designation by the Pharmaceuticals and Medical Devices Agency, the pharmaceuticals regulator of Japan.It was designed to provide easier access to novel advanced treatments. [1]
It is commonly known as Kōrō-shō (厚労省) in Japan. The ministry provides services on health, labour and welfare. The ministry provides services on health, labour and welfare. It was formed with the merger of the former Ministry of Health and Welfare or Kōsei-shō ( 厚生省 ) and the Ministry of Labour or Rōdō-shō ( 労働省 ) .
The tax and transfer system in Japan (MHLW 2017) Japan's welfare state has a non-typical conservative regime. Similar to other conservative countries, Japan has an occupational segmented social insurance system. Pre-war Japan once adopted a German-style social policy. Japan also borrowed ideas of pensions and health from the German system.
The Japanese Adverse Drug Event Report (JADER) database is a spontaneous reporting system of drug adverse events which is managed by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. [1] It has been available since 2012. [1]
PMDA may refer to: Pharmaceuticals and Medical Devices Agency , a Japanese governmental organization, similar in function to the Food and Drug Administration (FDA) in the US Plutonium Management and Disposition Agreement , an agreement between the United States and Russia signed in 2000
A Japanese Accepted Name (Japanese: 日本医薬品一般的名称, Hepburn: Nihon Iyakuhin Ippan-teki Meishō) (JAN) is the official non-proprietary or generic name given to a pharmaceutical substance by the Government of Japan. [1] [2]